title: Our perspective of the treatment of naevus of Ota with 1,064-, 755- and 532-nm wavelength lasers.
abstract: Naevus of Ota (NO) is a disfiguring pigmentary disorder affecting the face. Q-switched neodymium-doped yttrium aluminium garnet (QS Nd:YAG)-1,064 nm is a standard laser treatment because it causes highly selective destruction of melanin within the aberrant dermal melanocytes. However, not all lesions respond. This study aims to evaluate the efficacy/safety of QS Nd:YAG-1,064 nm and the shorter wavelength QS Alexandrite-755 nm and QS Nd:YAG-532 nm lasers in treating NO. Data were evaluated from 21 patients treated in our laser centre from 2004 to 2012. Lesional skin was irradiated with QS-532 nm/QS-755 nm/QS-1,064 nm, with settings titrated according to responses. All received initial test patches to direct initial wavelength choice, with subsequent treatments at 3-monthly intervals until clearance/lack of further response. Laser modality was switched following repeated test patches if there was no or no sustained improvement. Two thirds of patients had ≥ 90% improvement compared to baseline photographs. In 20% of patients, QS-1,064 nm was most efficacious with 97% mean improvement. The mean improvement was 80% for those in whom QS-755 nm was superior, and 90% for QS-532 nm. Median number of overall laser treatments was 8 (range 4-13). Number of treatments required varied significantly according to lesional colour and site: grey lesions and those on the forehead/temple were most resistant. We confirm successful treatment of NO with QS Nd:YAG-1,064 nm and the shorter wavelength QS-755 nm/QS-532 nm lasers without serious or irreversible side effects. We recommend judicious test patch analysis before treatment and a modality switch if complete clearance is not obtained.
authors: Laser Division, The Dermatology Centre, Salford Royal NHS Foundation Trust, Stott Lane, Manchester, M6 8HD, UK.
authors: S J
authors: SJ
authors: Felton
authors: F
authors: F
authors: Al-Niaimi
authors: J E
authors: JE
authors: Ferguson
authors: V
authors: V
authors: Madan
mesh_terms: D000293:Adolescent; D000328:Adult; D001608:Beryllium / Q000009:adverse effects; D003710:Demography; D005260:Female; D006801:Humans; D053685:Laser Therapy / Q000009:adverse effects; D053844:Lasers, Solid-State / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009507:Nevus of Ota / Q000473:pathology / Q000628:therapy*; D055815:Young Adult
chemical_list: C112654:alexandrite; D001608:Beryllium
references: N Engl J Med. 1994 Dec 29;331(26):1745-50
references: 7984195
references: AMA Arch Ophthalmol. 1956 Dec;56(6):830-2
references: 13371988
references: Br J Dermatol. 1975 Dec;93(6):639-43
references: 1220811
references: J Cutan Aesthet Surg. 2008 Jul;1(2):80-4
references: 20300349
references: Virchows Arch. 1997 Jul;431(1):63-71
references: 9247634
references: Arch Dermatol. 1967 Feb;95(2):187-95
references: 6018994
references: Plast Reconstr Surg. 2005 May;115(6):1769-73
references: 15861089
references: Dermatol Clin. 1997 Jul;15(3):355-72
references: 9189674
references: Indian J Dermatol Venereol Leprol. 2012 Mar-Apr;78(2):187-9; author reply 189-90
references: 22421653
references: Dermatologica. 1991;183(3):169-72
references: 1743382
references: Plast Reconstr Surg. 1995 Apr;95(4):703-11
references: 7892315
references: Ann Plast Surg. 1995 Feb;34(2):180-6
references: 7741438
references: Dermatologica. 1991;182(2):89-93
references: 2050240
references: Indian J Dermatol Venereol Leprol. 2011 Sep-Oct;77(5):565-70
references: 21860154
references: Br J Dermatol. 2004 Jun;150(6):1148-53
references: 15214902
references: J Invest Dermatol. 1989 Jul;93(1):28-32
references: 2746004